DICE Therapeutics (DICE) Stock Forecast, Price Target & Predictions
DICE Stock Forecast
DICE Therapeutics stock forecast is as follows: an average price target of $60.00 (represents a 26.18% upside from DICE’s last price of $47.55) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
DICE Price Target
The average price target for DICE Therapeutics (DICE) is $60.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $60.00. This represents a potential 26.18% upside from DICE's last price of $47.55.
DICE Analyst Ratings
According to 2 Wall Street analysts, DICE Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DICE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DICE Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 11, 2022 | Emily Bodnar | H.C. Wainwright | $60.00 | $40.25 | 49.07% | 26.18% |
| Jul 18, 2022 | Emily Bodnar | H.C. Wainwright | $40.00 | $16.06 | 149.07% | -15.88% |
The latest DICE Therapeutics stock forecast, released on Oct 11, 2022 by Emily Bodnar from H.C. Wainwright, set a price target of $60.00, which represents a 49.07% increase from the stock price at the time of the forecast ($40.25), and a 26.18% increase from DICE last price ($47.55).
DICE Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $47.55 | $47.55 | $47.55 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of DICE Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DICE Therapeutics's last price of $47.55. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2022 | Evercore ISI | Outperform | Outperform | Hold |
| Jul 18, 2022 | H.C. Wainwright | - | Buy | Initialise |
DICE Therapeutics's last stock rating was published by Evercore ISI on Oct 11, 2022. The company gave DICE a "Outperform" rating, the same as its previous rate.
DICE Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| IMCR | Immunocore | $33.55 | $75.50 | 125.04% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.14 | $79.33 | 55.12% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
| KDNY | Chinook Therapeutics | $40.39 | $30.00 | -25.72% | Buy |
DICE Forecast FAQ
Is DICE Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, DICE Therapeutics (DICE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of DICE's total ratings.
What is DICE's price target?
DICE Therapeutics (DICE) average price target is $60 with a range of $60 to $60, implying a 26.18% from its last price of $47.55. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will DICE Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DICE stock, the company can go up by 26.18% (from the last price of $47.55 to the average price target of $60), up by 26.18% based on the highest stock price target, and up by 26.18% based on the lowest stock price target.
Can DICE Therapeutics stock reach $70?
DICE's average twelve months analyst stock price target of $60 does not support the claim that DICE Therapeutics can reach $70 in the near future.